ARE Alexandria Real Estate Equities, Inc.

Investors need to pay close attention to ARE stock based on the movements in the options market lately.

As Alexandria Real Estate Equities has underperformed relative to the real estate sector over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Baron Capital, an investment management company, released its Q2 2026 letter for the “Baron Real Estate Income Fund.” The Fund gained 12.18% (Institutional Shares) during the quarter, modestly outperforming the MSCI US REIT Index, which increased 11.84%. The letter can be downloaded here. Its long-term performance also remains strong, with Morningstar ranking it the #2 […]

The insider sold 10,000 shares but still holds approximately 103,000 shares.

On August 3, Alexandria Real Estate Equities (NYSE:ARE) reported a Q2 2026 net loss of $0.43 per diluted share, narrower than the $0.64 loss posted a year earlier, while first-half net income swung to $1.68 per share from a loss of $0.71 in H1 2025. Funds from operations, the metric real estate investors watch most […]

Postal Realty Trust (PSTL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alexandria Real Estate Equities (ARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alexandria Real Estate Equities (ARE) is back in focus after announcing plans to release third quarter 2026 results on October 26, followed by a conference call and webcast with investors on October 27. Recent trading has been mixed for Alexandria Real Estate Equities, with a 7 day share price return of 15.4% and a 90 day share price return of 5.95% from a US$52.90 level, yet the 1 year total shareholder return has declined 30.57%. Compare Alexandria Real Estate Equities with a curated group...

Alexandria Real Estate Equities has seen its stock fall sharply over the past five years, yet current valuation checks suggest the shares trade at a discount to what the company's cash flows and market multiples imply as a reasonable intrinsic value. The stock has declined about 68% over five years, which puts the current share price in focus for investors assessing whether sentiment has moved further than fundamentals. A recent US$1b junior subordinated notes issue at a fixed to fixed reset...

Alexandria Real Estate has underperformed the broader market over the past year, and analysts remain skeptical about the stock’s prospects.

Alexandria Real Estate Equities (NYSE:ARE) reported second-quarter 2026 adjusted funds from operations of $1.73 per diluted share and reaffirmed the midpoint of its full-year guidance at $6.40 per share, while narrowing the annual range to plus or minus $0.05. The life science real estate company s

Alexandria's Q2 FFO beat estimates as leasing tops 1 million RSF, rental-rate declines ease and 1.4 million RSF awaits lease commencement.

While the top- and bottom-line numbers for Alexandria Real Estate Equities (ARE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Alexandria Real Estate Equities (ARE) delivered FFO and revenue surprises of +4.85% and +2.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Investors need to pay close attention to ARE stock based on the movements in the options market lately.

ARE's Q2 results are likely to face pressure from lower occupancy, lease expirations and weaker same-property revenues.

American Tower (AMT) delivered FFO and revenue surprises of 0.00% and +1.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alexandria Real Estate Equities (NYSE:ARE) has delivered a 427,000 RSF research and development facility for Bristol Myers Squibb at its San Diego megacampus. The new state-of-the-art R&D hub marks an operational milestone for the company and reflects demand from a large multinational pharmaceutical tenant. Alexandria Real Estate Equities focuses on life science and R&D campuses that serve large pharmaceutical and biotech companies. The new San Diego facility for Bristol Myers Squibb adds...

Alexandria Real Estate Equities (ARE) has entered an escrow agreement tied to a planned fourth amended and restated credit agreement, which could provide a $5b unsecured revolving credit facility and an additional $1b accordion feature. See our latest analysis for Alexandria Real Estate Equities. The escrowed credit agreement news arrives after a mixed period for Alexandria Real Estate Equities, with short term momentum improving, including a 7 day share price return of 4.10%, while the 1...